About This Calculator
The Actemra (tocilizumab) Dosing Calculator is a clinical support tool designed to help healthcare professionals determine appropriate dosing regimens based on FDA-approved indications. This guide explains the calculator's outputs, use cases, and provides supplementary clinical information for safe and effective administration.
Outputs
After entering the required patient information, the calculator will provide the following outputs:
- Recommended Dose: The calculated dose in milligrams (mg). For intravenous (IV) administration, this is weight-based and may be capped at a maximum of 800 mg. For subcutaneous (SQ) administration, a fixed dose is typically provided.
- Dosing Frequency: The recommended schedule for administration, such as every week, every 2 weeks, or every 4 weeks, which varies by indication and patient weight.
- Administration Details (IV): For IV infusions, the calculator specifies the volume of drug to withdraw from vials, the final dilution volume (typically 50 mL or 100 mL), and the standard infusion time (60 minutes).
- Administration Details (SQ): For SQ injections, the calculator notes the available prefilled syringe or autoinjector strength (162 mg).
How to Use
To use the calculator effectively, follow these steps:
- Select Indication: Choose the patient's FDA-approved indication from the dropdown menu (e.g., Rheumatoid Arthritis, Giant Cell Arteritis).
- Enter Patient Weight: Input the patient's weight and select the correct unit (kg or lbs). The calculator will convert lbs to kg for its calculations.
- Select Route of Administration: Choose between Intravenous (IV) or Subcutaneous (SQ) administration. Available routes are automatically filtered based on the selected indication.
- Calculate: Click the "Calculate Dose" button to generate the dosing recommendation based on the provided inputs.
Dosing Overview
Actemra dosing varies significantly based on indication, patient weight, and administration route. The following table summarizes the general dosing principles as implemented in the calculator.
| Indication | Route | Patient Group | Typical Dosing Regimen |
|---|---|---|---|
| Rheumatoid Arthritis (RA) | IV | Adults | 4 mg/kg every 4 weeks, may increase to 8 mg/kg. Max 800 mg/dose. |
| Rheumatoid Arthritis (RA) | SQ | Adults <100 kg | 162 mg every other week, may increase to every week. |
| Rheumatoid Arthritis (RA) | SQ | Adults ≥100 kg | 162 mg every week. |
| Giant Cell Arteritis (GCA) | SQ | Adults | 162 mg every week or every other week. |
| Systemic Sclerosis-Associated ILD (SSc-ILD) | SQ | Adults | 162 mg every week. |
| Polyarticular JIA (PJIA) | IV | ≥2 years, <30 kg | 10 mg/kg every 4 weeks. |
| Polyarticular JIA (PJIA) | IV | ≥2 years, ≥30 kg | 8 mg/kg every 4 weeks. Max 800 mg/dose. |
| Systemic JIA (SJIA) / Cytokine Release Syndrome (CRS) | IV | ≥2 years, <30 kg | 12 mg/kg. |
| Systemic JIA (SJIA) / Cytokine Release Syndrome (CRS) | IV | ≥2 years, ≥30 kg | 8 mg/kg. Max 800 mg/dose. |
| COVID-19 | IV | Hospitalized Adults | 8 mg/kg as a single dose. Max 800 mg/dose. |
Switching
Patients with Rheumatoid Arthritis (RA), Polyarticular JIA (PJIA), or Systemic JIA (SJIA) may switch between Actemra IV and SQ formulations.
- Switching from IV to SQ: Administer the first subcutaneous dose at the time of the next scheduled intravenous dose.
- Switching from SQ to IV: Administer the first intravenous dose at the time of the next scheduled subcutaneous dose.
Consult the full prescribing information for specific guidance on transitioning between formulations.
Missed Dose
- Subcutaneous (SQ) Injection: If a patient misses a scheduled SQ dose, they should be advised to inject the missed dose as soon as they remember. They should then take their next dose at the regularly scheduled time.
- Intravenous (IV) Infusion: If a patient misses a scheduled IV infusion, they should contact their healthcare provider to reschedule the appointment as soon as possible.
Safety Alerts
Boxed Warning: Serious Infections
Patients treated with Actemra are at an increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. Actemra should be discontinued if a patient develops a serious infection. Screen for latent TB prior to initiating therapy.
Other Key Risks
- Gastrointestinal (GI) Perforation: Use with caution in patients who may be at increased risk for GI perforation.
- Hepatotoxicity: Serious drug-induced liver injury has been observed. Monitor liver function tests (ALT/AST) at baseline and periodically during treatment.
- Laboratory Abnormalities: Treatment can lead to neutropenia, thrombocytopenia, and elevated lipid parameters. Monitor ANC, platelets, and lipids as recommended in the prescribing information.
- Hypersensitivity Reactions: Anaphylaxis and serious hypersensitivity reactions can occur. Ensure appropriate medical support is available.
Frequently Asked Questions
Why is the maximum IV dose capped at 800 mg?
The approved prescribing information for Actemra specifies that IV doses should not exceed 800 mg per infusion, even if the patient's weight-based calculation (e.g., 8 mg/kg) results in a higher number. This calculator automatically applies this 800 mg cap.
How does the SQ dosing for Rheumatoid Arthritis change based on weight?
For adults with RA, the SQ dosing schedule depends on body weight. Patients weighing less than 100 kg typically start at 162 mg every other week, while patients weighing 100 kg or more receive 162 mg every week.
Why are dosing parameters different for patients above or below 30 kg in JIA and CRS?
Clinical studies established different weight-based dosing regimens for pediatric patients to achieve similar drug exposures. Patients weighing less than 30 kg require a higher mg/kg dose (10 or 12 mg/kg) compared to those 30 kg or more (8 mg/kg) to reach therapeutic targets.
Why are only certain routes available for specific indications?
The available routes (IV or SQ) are determined by the clinical trials that led to FDA approval for each specific indication. For example, Actemra for Giant Cell Arteritis (GCA) was studied and approved only as a subcutaneous injection.
Can I use this calculator for patients under 2 years of age?
No. The safety and efficacy of Actemra have not been established in pediatric patients under 2 years of age. This calculator is intended for use within the FDA-approved age ranges only.
What should I do if my patient has abnormal lab results during treatment?
The prescribing information provides specific guidance for dose modification or interruption based on elevated liver enzymes (ALT/AST), low absolute neutrophil count (ANC), or low platelet count. Refer to the "Dose Modification Guidance" section in the tool or the full prescribing information.
Does this tool calculate dose adjustments for renal or hepatic impairment?
No. This tool does not provide recommendations for patients with renal or hepatic impairment. Actemra has not been studied in these populations. Consult the full prescribing information for details.
What infusion details does the calculator provide for IV administration?
The calculator specifies the total mg dose, the volume of drug (in mL) to withdraw from vials (based on a 20 mg/mL concentration), the final volume for dilution in 0.9% NaCl (either 50 mL or 100 mL), and the standard 60-minute infusion time.
References
- ACTEMRA® (tocilizumab) Prescribing Information. Genentech, Inc. Revised: 12/2023. Available at: FDA.gov.
- Genentech. Actemra for Healthcare Professionals. Available at: actemra-hcp.com.
- Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016;68(1):1-26.
- National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines: Interleukin-6 Inhibitors. Available at: covid19treatmentguidelines.nih.gov.
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com